The most promising compounds were adenosine 5′-monophosphate (A5MP) and 5-aminoimidazole-4-carboxamide-ribonucleotide (AICAR) 5′ monophosphate (ZMP), which inhibited ssDNA binding to RAD52 and the growth of BRCA1-deficient HCC breast cancer cells. The gene discussed is RAD52; the disease is hepatocellular carcinoma.